Evidence map›Paper›PMID 38723164›Full record

ArticleProtein science : a publication of the Protein Society2024

In silico identification of a novel Cdc2-like kinase 2 (CLK2) inhibitor in triple negative breast cancer.

Cheng-Chiao Huang, Chia-Ming Hsu, Min-Wu Chao, Kai-Cheng Hsu, Tony Eight Lin, Shih-Chung Yen, Huang-Ju Tu, Shiow-Lin Pan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cheng-Chiao HuangPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan.
Chia-Ming HsuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Min-Wu ChaoSchool of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
Kai-Cheng HsuPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan.ORCID 0000-0002-9022-6673
Tony Eight LinPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan.
Shih-Chung YenWarshel Institute for Computational Biology, The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong, China.
Huang-Ju TuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Shiow-Lin PanPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan.ORCID 0000-0001-7449-3539

Funding

Academia Sinica AS-BRPT-112-11Ministry of Science and Technology MOST 112-2320-B-038-052TMU Research Center of Cancer Translational Medicine from the Higher Education Sprout Project by the Ministry of Education
6 · The paper itself

Abstract

Dysregulation of RNA splicing processes is intricately linked to tumorigenesis in various cancers, especially breast cancer. Cdc2-like kinase 2 (CLK2), an oncogenic RNA-splicing kinase pivotal in breast cancer, plays a significant role, particularly in the context of triple-negative breast cancer (TNBC), a subtype marked by substantial medical challenges due to its low survival rates. In this study, we employed a structure-based virtual screening (SBVS) method to identify potential CLK2 inhibitors with novel chemical structures for treating TNBC. Compound 670551 emerged as a novel CLK2 inhibitor with a 50% inhibitory concentration (IC

Indexed as

Protein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesTriple Negative Breast NeoplasmsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationFemaleHumansMolecular Docking SimulationAntineoplastic AgentsClk dual-specificity kinasesProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesCLK2drug discoverykinase inhibitorstructure‐based virtual screeningtriple‐negative breast cancer

Identifiers

PMID38723164
PMCPMC11081522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.